CardioGraft-MC® Decellularized Pulmonary Patch
CardioGraft-MC Decellularized Pulmonary Patch is used for right ventricular outflow tract repair and reconstruction.
- Human Tissue: Closely resembles autograft; compliant, flexible, easy to handle and suture.
- Resistant to Infection: Natural ability to resist infection.1-3
- Convenient: Availability in various sizes to best fit the patient’s anatomy.
- Decellularized: Patented Matracell® technology removes ≥99% of donor DNA.3
- Clinically Effective: Lower potential for reoperation or intervention. Proven resistance to calcification and stenosis.1,2
- Efficient: Potentially reduces operating room time and cost by reducing the rate of serious adverse events and reoperations.4
Repair of the right ventricular outflow tract for:
- Tetralogy of Fallot
- Truncus Arteriosis
- Transposition of the Great Arteries
- Pulmonary Stenosis/Atresia
|DPPGK||Trunk||W = 25 - 50 mm in 5 mm increments; L = 30 - 80 mm in 5 mm increments|
|DPPGN||Branch||W = 25 - 50 mm in 5 mm increments; L = 30 - 80 mm in 5 mm increments|
- Lofland GK, et al. Initial pediatric cardiac experience with decellularized allograft patches. Ann of Thoracic Surg, 2012;93:968-71.
- Hopkins RA, et al. Pulmonary Arterioplasty With Decellularized Allogeneic Patches. Ann of Thoracic Surg, Vol. 97, Issue 4, April 2014, Pages 1407-1412.
- LifeNet Health data on file: PQ-07-078.
- CardioGraft-MC (also known as Matracell®) Decellularized Cardiac Patch Allograft Cost-Effectiveness Analysis Musculoskeletal Clinical Regulatory Advisors, June 2014.